The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month.
The real-time PCR-based test runs on the BD Max system and comes in a single tube that snaps into the BD MAX extraction cartridge.
The Taiwanese research team that developed the method showed in a new study that it could better detect BRAF mutations than conventional PCR plus Sanger sequencing.
The firm sees the new panel as an important step forward in its strategy to further penetrate the molecular diagnostics market with its qPCR products.
The companies will work together to pursue US Food and Drug Administration clearance for a workflow combining Siemens' sample prep module and Thermo's qPCR instrument.
The company will use the funding to prepare for the 2017 launch of its DiagCore integrated molecular and immunoassay near-patient testing platform.